Search PubMed⌕ Search

Biomedical subjects

A Takeuchi

Publications and source records attributed to A Takeuchi.

At least 343 records · Page 19Linked to original sources
PubMed1987

A case of lowered eosinophilic leucocyte peroxidase activity found unexpectedly using an automated haematology analyser (the Technicon H6000 system)

The Technicon H6000 system simultaneously determines blood cell and leucocyte differential counts automatically using cytochemistry and cell size measurements. Part of the information provided by this instrument is a plot of peroxidase staining intensity against leucocyte cell size called 'the leucocyte peroxidase distribution display'. Recently, an abnormal leucocyte peroxidase distribution display was observed, on a sample from a post-operative lung cancer patient, in which eosinophilic leucocytes did not react with peroxidase. Neutrophils reacted in a normal way with this sample. The eosinophils were further examined by electron microscopy and manual peroxidase staining. Some peroxidase positive granules were observed in the eosinophilic leucocytes. The abnormal leucocyte peroxidase distribution display was found to be due to a separate group of eosinophilic leucocytes with lowered peroxidase activity.

Blood Cell Count↗
PubMed1987

Significance of renal hyaline arteriolosclerosis and tubulo-interstitial change in IgA glomerulonephropathy and focal glomerular sclerosis.

The relationship between glomerular sclerosis and hyaline arteriolosclerosis (HA) or tubulo-interstitial (T-I) change was investigated in 66 patients with IgA glomerulonephropathy (IgA-GN) and in 12 patients with idiopathic focal segmental glomerulosclerosis (FGS). More than a 10% incidence of global sclerosis was noted in 15 patients with IgA-GN and in 9 patients with FGS. There was no significant discrepancy of age between patients with IgA-GN and those with FGS (IgA-GN: 37.5 +/- 12.5; FGS: 35.7 +/- 10.3). In patients with IgA-GN, 7 out of 15 were HA-positive (46.7%), whereas in patients with FGS, 7 out of 9 were HA-positive (77.8%). However, a close correlation was observed between glomerular sclerosis and T-I change only in patients with IgA-GN (r = 0.82; p less than 0.001). The results suggested that in the case of IgA-GN, T-I change was related to the prognosis of glomerular sclerosis. In addition, it is assumed that a possible correlation exists between FGS and HA.

Adolescent↗
PubMed1987

The transmitter role of glutamate in nervous systems.

Acceptance of L-glutamate as an excitatory transmitter was relatively slow compared to other transmitters, such as GABA. However, the transmitter role of L-glutamate has received more attention recently. In the crustacean neuromuscular junction L-glutamate fulfills most of the criteria for the transmitter identification. Studies on the glutamate receptor antagonist suggest that L-glutamate may also be the transmitter at the squid giant synapse. L-Glutamate may be the excitatory transmitter in many parts of CNS, although the evidence for this hypothesis is still not complete. The role of L-aspartate as the transmitter in CNS is not clear but its contribution may be less than that of L-glutamate. Glutamate receptors have been classified into three groups according to pharmacological properties. However, recent observations suggest that the situation seems more complicated than previously expected and more detailed comparison between synaptic potentials and glutamate action is needed.

Animals↗
PubMed1987

Oral prostaglandin E1 as a therapeutic modality for leg ulcers in Behçet's disease.

Prostaglandin E1 (PGE1) has been generally given only by intravascular injection. Recently, an oral PGE1 named OP1206 has been developed. OP1206 is a potent inhibitor of platelet aggregation as well as a strong vasodilator, and its half-life in humans is extremely prolonged because it is not metabolized in the lungs. Leg ulceration is one of the cutaneous manifestations in Behçet's disease and sometimes is very difficult to treat. In this investigation five patients having Behçet's disease with leg ulcers were treated with OP1206. All of the patients had the leg ulcers for more than 2 months. Fifteen micrograms of OP1206 was given initially, and the dosage was increased to 30 micrograms whenever there were no adverse effects. All the patients were soon able to tolerate the drug and increased dosage. Within 2 weeks, regeneration of granulomatous tissues was observed in all cases. Furthermore, the leg ulcers healed within one year. Only one patient developed diarrhoea, but this symptom disappeared when he adjusted to the dosage. The findings strongly indicate that OP1206 is a safe and promising drug for the treatment of leg ulcers in Behçet's disease.

Administration, Oral↗